Journal of Surgery Concepts & Practice ›› 2023, Vol. 28 ›› Issue (02): 110-114.doi: 10.16139/j.1007-9610.2023.02.05
• Experts forum • Previous Articles Next Articles
Received:
2023-03-28
Online:
2023-03-25
Published:
2023-06-06
CLC Number:
XING Ying, CHENG Shi. Neoadjuvant therapy for gallbladder cancer: current status and challenge[J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 110-114.
[1] |
HUANG J, PATEL H K, BOAKYE D, et al. Worldwide distribution, associated factors, and trends of gallbladder cancer: a global country-level analysis[J]. Cancer Lett, 2021, 521:238-251.
doi: 10.1016/j.canlet.2021.09.004 pmid: 34506845 |
[2] |
CHAN K M, YEH T S, JAN Y Y, et al. Laparoscopic cholecystectomy for early gallbladder carcinoma: long-term outcome in comparison with conventional open cholecystectomy[J]. Surg Endosc, 2006, 20(12):1867-1871.
doi: 10.1007/s00464-005-0195-5 pmid: 17031747 |
[3] | 中华医学会外科学分会胰腺外科学组, 中国研究型医院学会胰腺疾病专业委员会. 中国胰腺癌新辅助治疗指南(2020版)[J]. 中华外科杂志, 2020, 58(9):657-667. |
Study Group of Pancreatic Surgery in China Society of Surgery of Chinese Medical Association, Pancreatic Disease Committee of China Research Hospital Association. The guideline for neoadjuvant therapy of pancreatic cancer in China (2020 edition)[J]. Chin J Surg, 2020, 58(9):657-667. | |
[4] | 中国医疗保健国际交流促进会肝脏肿瘤分会, 中国医学科学院北京协和医学院肿瘤医院消化道肿瘤多学科协作组. 肝细胞癌新辅助及转化治疗中国专家共识[J]. 肝癌电子杂志, 2022, 9(1):23-28. |
Liver Tumor Committee of China International Exchange and Promotion Association for Medical and Healthcare, MDT Group of Gastrointestinal Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma[J]. Electronic J Liver Tumor, 2022, 9(1):23-28. | |
[5] | 中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科专业委员会. 胆囊癌诊断和治疗指南(2019版)[J]. 中华外科杂志, 2020, 58(4):243-251. |
Branch of Biliary Surgery, Chinese Surgical Society, Chinese Committee of Biliary Surgeons. Guideline for the diagnosis and treatment of gallbladder carcinoma (2019 edition)[J]. Chin J Surg, 2020, 58(4):243-251. | |
[6] |
BENSON A B, D'ANGELICA M I, ABBOTT D E, et al. Hepatobiliary Cancers,version 2.2021,NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2021, 19(5):541-565.
doi: 10.6004/jnccn.2021.0022 URL |
[7] |
HAKEEM A R, PAPOULAS M, MENON K V. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer - a systematic review[J]. Eur J Surg Oncol, 2019, 45(2):83-91.
doi: S0748-7983(18)31295-2 pmid: 30287098 |
[8] |
NAVEED S, QARI H, THAU C M, et al. Neoadjuvant chemotherapy for advanced gallbladder cancer: do we have enough evidence? A systematic review[J]. Euroasian J Hepatogastroenterol, 2021, 11(2):87-94.
doi: 10.5005/jp-journals-10018-1348 pmid: 34786362 |
[9] |
CHAUDHARI V A, OSTWAL V, PATKAR S, et al. Outcome of neoadjuvant chemotherapy in “locally advanced/borderline resectable”gallbladder cancer: the need to define indications[J]. HPB (Oxford), 2018, 20(9):841-847.
doi: 10.1016/j.hpb.2018.03.008 URL |
[10] |
SIROHI B, MITRA A, JAGANNATH P, et al. Neoadjuvant chemotherapy in patients with locally advanced gallbladder cancer[J]. Future Oncol, 2015, 11(10):1501-1509.
doi: 10.2217/fon.14.308 pmid: 25963427 |
[11] | 付佳禄, 雷建军, 张东, 等. 胆囊癌新辅助治疗研究现状[J]. 岭南现代临床外科, 2021, 21(3):257-264. |
FU J L, LEI J J, ZHANG D, et al. Current research status of neoadjuvant treatment for gallbladder cancer[J]. Lingnan Mod Clin Surg, 2021, 21(3):257-264. | |
[12] |
OZER M, GOKSU S Y, SANFORD N N, et al. A propensity score analysis of chemotherapy use in patients with resectable gallbladder cancer[J]. JAMA Netw Open, 2022, 5(2):e2146912.
doi: 10.1001/jamanetworkopen.2021.46912 pmid: 35171262 |
[13] | 中华医学会外科学分会胆道外科学组. 胆囊癌诊断和治疗指南(2015版)[J]. 中华消化外科杂志, 2015, 14(11):881-890. |
Branch of Biliary Surgery, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the diagnosis and treatment of gallbladder cancer (2015 edition)[J]. Chin J Dig Surg, 2015, 14(11):881-890. | |
[14] |
VOESCH S, BITZER M, BLÖDT S, et al. S3-leitlinie: diagnostik und therapie des hepatozellularen karzinoms und biliarer karzinome-version 2.0-Juni 2021,AWMF-registernummer: 032-053OL[J]. Z Gastroenterol, 2022, 60(1):e131-e185.
doi: 10.1055/a-1589-7585 URL |
[15] |
CREASY J M, GOLDMAN D A, DUDEJA V, et al. Systemic chemotherapy combined with resection for locally advanced gallbladder carcinoma:surgical and survival outcomes[J]. J Am Coll Surg, 2017, 224(5):906-916.
doi: 10.1016/j.jamcollsurg.2016.12.058 URL |
[16] |
SAHAI V, CATALANO P J, ZALUPSKI M M, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma:a phase 2 clinical trial[J]. JAMA Oncol, 2018, 4(12):1707-1712.
doi: 10.1001/jamaoncol.2018.3277 URL |
[17] |
SHROFF R T, JAVLE M M, XIAO L, et al. Gemcitabine,cisplatin,and nab-paclitaxel for the treatment of advanced biliary tract cancers:a phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(6):824-830.
doi: 10.1001/jamaoncol.2019.0270 URL |
[18] |
LAMARCA A, PALMER D H, WASAN H S, et al. Advanced biliary cancer working group. second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06):a phase 3,open-label,randomised,controlled trial[J]. Lancet Oncol, 2021, 22(5):690-701.
doi: 10.1016/S1470-2045(21)00027-9 URL |
[19] |
ROA J C, GARCÍA P, KAPOOR V K, et al. Gallbladder cancer[J]. Nat Rev Dis Primers, 2022, 8(1):69.
doi: 10.1038/s41572-022-00398-y pmid: 36302789 |
[20] |
MERIC-BERNSTAM F, BEERAM M, HAMILTON E, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers:a phase 1, dose-escalation and expansion study[J]. Lancet Oncol, 2022, 23(12):1558-1570.
doi: 10.1016/S1470-2045(22)00621-0 URL |
[21] |
DEMOLS A, BORBATH I, VAN DEN EYNDE M, et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic bi-liary tumors: reachin,a randomized,double-blind,phase Ⅱ trial[J]. Ann Oncol, 2020, 31(9):1169-1177.
doi: 10.1016/j.annonc.2020.05.018 URL |
[22] | JAVLE M M, OH D Y, IKEDA M, et al. Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase Ⅱ study (TreeTopp)[J]. ESMO Open, 2022, 7(1):100314. |
[23] | HINDSON J. Gemcitabine and cisplatin plus immunotherapy in advanced biliary tract cancer:a phase Ⅱ study[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(5):280. |
[24] | DE ARETXABALA X, LOSADA H, MORA J, et al. Quimiorradioterapia de neoadyuvancia en cáncer de vesícula biliar neoadjuvant chemoradiotherapy in gallbladder cancer[J]. Rev Med Chil, 2004, 132(1):51-57. |
[25] |
AGRAWAL S, MOHAN L, MOURYA C, et al. Radiological downstaging with neoadjuvant therapy in unresec-table gall bladder cancer cases[J]. Asian Pac J Cancer Prev, 2016, 17(4):2137-2140.
doi: 10.7314/APJCP.2016.17.4.2137 URL |
[26] |
ENGINEER R, GOEL M, CHOPRA S, et al. Neoadjuvant chemoradiation followed by surgery for locally advanced gallbladder cancers:a new paradigm[J]. Ann Surg Oncol, 2016, 23(9):3009-3015.
doi: 10.1245/s10434-016-5197-0 URL |
[27] | LOYAL A, CHOPRA S, GOEL M, et al. Predictors of toxicity after neoadjuvant chemoradiotherapy for locally advanced gall bladder cancer[J]. Indian J Cancer, 2022, 59(3):368-374. |
[28] | 吉吉伍迁, 向毅, 黄洁, 等. 进展期胆囊癌新辅助治疗临床疗效及安全性研究的meta分析[J]. 重庆医学, 2021, 50(20):3541-3545. |
JI JI W Q, XIANG Y, HUANG J, et al. Clinical efficacy and safety of neoadjuvant therapy for advanced gallbladder cancer:a meta-analysis[J]. Chongqing Med, 2021, 50(20):3541-3545. | |
[29] |
SIEBENHÜNER A R, SEIFERT H, BACHMANN H, et al. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: a prospective single center phase Ⅱ study[J]. BMC Cancer, 2018, 18(1):72.
doi: 10.1186/s12885-017-3967-0 URL |
[30] |
PRIMROSE J N, FOX R P, PALMER D H, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP):a randomised,controlled,multicentre,phase 3 study[J]. Lancet Oncol, 2019, 20(5):663-673.
doi: 10.1016/S1470-2045(18)30915-X URL |
[1] | WANG Yuanjiang, ZOU Hao. Clinical study on comprehensive treatment of gallbladder cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 171-176. |
[2] | LI Jianfang, YU Junxian, YAN Chao, ZHU Zhenggang, LIU Bingya. Hotspots in basic and translational research of gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 7-16. |
[3] | WANG Jieqiang, MA Dekui. Study on trophoblast cell-surface antigen 2 gene and triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 473-477. |
[4] | ZHANG Jixiang, XIE Zhihua, LI Wei, JIANG Xiaoqing. Classification of intrahepatic cholangiocarcinoma and hot topics in surgical treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 478-482. |
[5] | GUO Yang, GUO Tian′an, XU Ye. Recent advance in neoadjuvant chemotherapy for rectal cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(04): 370-374. |
[6] | XU Zifeng, ZONG Yaping, LU Aiguo. Neoadjuvant therapy in patients with locally advanced colon cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 266-270. |
[7] | ZHANG Xihao, ZHANG Xinyun, CAO Manqing, ZHANG Jinliang, WANG Huaqi, ZHANG Su, FU Zhou, WANG Lu, ZHANG Ti. Both anti-angiogenesis and immunotherapy combined with interventional therapy in treatment of hepatocellular carcinoma: effect of hepatic artery infusion chemotherapy compared with hepatic artery chemoembolization [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 152-157. |
[8] | WANG Siying,ZHENG Xingling,QIN Wenxin. Could Cancer Patients Survive for a Long Time? [J]. Journal of Shanghai Jiao Tong University, 2021, 55(Sup.1): 49-50. |
[9] | ZONG Chunyan,SHEN Jianfeng. Can Immunotherapy Cure Cancer? [J]. Journal of Shanghai Jiao Tong University, 2021, 55(Sup.1): 53-54. |
[10] | Hongyuan LIU, Tongxin GE, Xiaoxi LIN. Progress in Targeted Therapy of Low-Flow Vascular Malformation [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2020, 16(3): 204-209. |
[11] | ZHANG Daojian, ZHANG Dexiang, WANG Jiwen, LU Pinxiang, LIU Houbao, LIU Han. Contrast-enhanced ultrasound in differential diagnosis of gallbladder cancer from xanthogranulomatous cholecystitis [J]. Journal of Surgery Concepts & Practice, 2020, 25(04): 322-325. |
[12] | CHEN Xianze, CHENG Xi, WU Haoxuan, ZHANG Tao, JI Xiaopin, ZHAO Ren. Preliminary research on colorectal cancer neoadjuvant therapy sensitivity through high-throughput transcriptome sequence [J]. Journal of Surgery Concepts & Practice, 2018, 23(01): 67-71. |
[13] | ZHAO Lijuan,ZHENG Jianghong,LIU Xiangdong,MAO Guangyu,DENG Chenliang,YANG Songlin. The Inhibition of iRGD-Exosomes-Doxorubicin on the Proliferation of Malignant Melanoma in Vitro [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2017, 13(1): 25-28. |
[14] | . [J]. Journal of Surgery Concepts & Practice, 2017, 22(01): 40-44. |
[15] | . [J]. Journal of Surgery Concepts & Practice, 2014, 19(02): 140-144. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||